Search

Your search keyword '"Hepatocyte Growth Factor Receptor"' showing total 651 results

Search Constraints

Start Over You searched for: Descriptor "Hepatocyte Growth Factor Receptor" Remove constraint Descriptor: "Hepatocyte Growth Factor Receptor"
651 results on '"Hepatocyte Growth Factor Receptor"'

Search Results

1. Genetic deletion or tyrosine phosphatase inhibition of PTPRZ1 activates c‐Met to up‐regulate angiogenesis and lung adenocarcinoma growth.

2. Exhaled phospholipid transfer protein and hepatocyte growth factor receptor in lung adenocarcinoma

3. Exhaled phospholipid transfer protein and hepatocyte growth factor receptor in lung adenocarcinoma.

4. Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis.

5. Phytochemicals Neogitogenin and Samogenin Hold Potentials for Hepatocyte Growth Factor Receptor-Targeted Cancer Treatment.

6. MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis.

7. 3‐phosphoinositide‐dependent protein kinase 1 (PDK1) mediates crosstalk between Src and Akt pathways in MET receptor signaling.

10. Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.

12. 沉默肝细胞生长因子受体c-Met表达对结肠癌细胞生物学特性的影响.

15. Prognostic significance of c‑Met, β‑catenin and FAK in patients with hepatocellular carcinoma following surgery.

16. Genetic Basis and Therapies for Vascular Anomalies

17. Pharmacophore Mapping Approach for Drug Target Identification: A Chemical Synthesis and in Silico Study on Novel Thiadiazole Compounds

18. An auxiliary binding interface of SHIP2-SH2 for Y292-phosphorylated FcγRIIB reveals diverse recognition mechanisms for tyrosine-phosphorylated receptors involved in different cell signaling pathways

19. Novel intergenic KIF5B-MET fusion variant in a patient with gastric cancer: A case report

20. VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

21. Functional analysis of isoflavones using patient-derived human colonic organoids

23. A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.

24. Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.

25. Anti-c-Met antibody bioconjugated with hollow gold nanospheres as a novel nanomaterial for targeted radiation ablation of human cervical cancer cell.

26. Pharmacophore Mapping Approach for Drug Target Identification: A Chemical Synthesis and in Silico Study on Novel Thiadiazole Compounds.

27. Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition

28. Overexpression of Platelet-Derived Growth Factor Receptor Α D842V Mutants Prevents Liver Regeneration and Chemically Induced Hepatocarcinogenesis via Inhibition of MET and EGFR

29. Transformation of Receptor Tyrosine Kinases into Glutamate Receptors and Photoreceptors

30. Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients

31. Hepatic Differentiation of Marmoset Embryonic Stem Cells and Functional Characterization of ESC-Derived Hepatocyte-Like Cells

32. Light-Induced Radiosynthesis of 89Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor

33. MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis

34. Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis

35. Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma

39. Epithelial Differentiation and the Control of Metastasis in Carcinomas

44. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?

45. Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies

46. 3‐phosphoinositide‐dependent protein kinase 1 (PDK1) mediates crosstalk between Src and Akt pathways in MET receptor signaling

49. Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Clinical and Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione Derivatives

50. Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)

Catalog

Books, media, physical & digital resources